Neutral orthophosphate solution as part of primary hyperoxaluria treatment. A case report

• Autores: Pablo Pérez Huertas
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 16, Nº. 3, 2014, págs. 217-220
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Primary hyperoxaluria type I is an autosomal recessive disease in which alanine-glyoxylate-transferase enzyme is affected resulting in increased oxalate excretion by the kidney and stones precipitation. The progressive kidney involvement could bring about an oxalate systemic accumulation. It is usually diagnosed in young people to cause renal complications. Used treatments were pyridoxine, which acts as a cofactor for alanine-glyoxylate-transferase and oxalate solubilizers; although the permanent treatment is a liver-kidney transplantation. We report a middle-aged woman who was diagnosed with primary hyperoxaluria after kidney transplantation. It was decided to add an uncommon oxalate solubilizer to the standard treatment which is not marketed in Spain: neutral orthophosphate. In this report we follow the development, efficacy and safety of this solubilizer during seven months of treatment